Maraviroc for HIV: Responses at 48 Weeks
/
RSS Feed
Jacob Lalezari
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
You may also like...
Earlier Interferon Reduces Disability in Patients With Multiple Sclerosis 15 Aug, 2007 - Tuberculosis: Non-Adherence to Treatment is a Major Obstacle to Therapy Success 9 Aug, 2007
- Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France 2 Aug, 2007
- Better Treatment for Addicts: New Urine Test for Street Heroin 3 Jan, 2006
